How We’re Mobilizing Our Resources to Help Find Solutions for COVID-19
Learn More
Press Release Archive
-
Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income CountriesStop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries
Joint efforts aim to accelerate scale-up of WHO-recommended all-oral treatment regimens – a transition urgently needed to help protect the health of people with drug resistant-tuberculosis who are particularly vulnerable during COVID-19 pandemicIn 2020, the initiative aims to reach at least 125,000 patients and could save National TB Programs in low- and middle-income countries up to USD$16 million -
Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola VaccineJohnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola VaccineThis marks the first major regulatory approval of a vaccine developed by JanssenThe Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technologyJanssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19
-
Johnson & Johnson to Host Investor Conference Call on Second-Quarter ResultsJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results
-
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus ErythematosusJanssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
-
Johnson & Johnson Announces Winners of 2020 Women in STEM2D Scholars AwardJohnson & Johnson Announces Winners of 2020 Women in STEM2D Scholars AwardThe six winners are assistant professors or senior lecturers and represent women leaders in the disciplines of Science, Technology, Engineering, Math, Manufacturing and Design;Each winner will receive $150,000 in funding and three years of mentorship from Johnson & Johnson to support cutting-edge research on clinical trials, origami-inspired robotics, planetary systems, hospital lighting, and the treatment of brain tumors and bowel diseases.
-
Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) AmyloidosisSubcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) AmyloidosisPhase 3 ANDROMEDA study investigated the first and only subcutaneous anti-CD38 monoclonal antibody in treatment of rare multi-system disease with a high unmet medical need andfor which there are currently no approved therapies
Data selected as late-breaking abstract and featured in press briefing at European Hematology Association (EHA) Annual Congress -
Johnson & Johnson to Participate in Bank of America Virtual ConferenceJohnson & Johnson to Participate in Bank of America Virtual Conference
-
Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of JulyJohnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of JulyJohnson & Johnson Continues to Build its Manufacturing Capacity and Partnerships to Meet Commitment and Global Need
-
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine RegimenJohnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine RegimenThe investigational Ebola vaccine regimen leverages Janssen’s established AdVac® and PER.C6® technologies and Bavarian Nordic’s MVA-BN® technologyThe AdVac® and PER.C6® technologies have been used to construct Janssen’s COVID-19, Zika, Respiratory Syncytial Virus (RSV) and HIV vaccine candidates
-
Johnson & Johnson to Participate in the Goldman Sachs 41st Annual Global Virtual Healthcare ConferenceJohnson & Johnson to Participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference